1. Home
  2. GTBP vs ULY Comparison

GTBP vs ULY Comparison

Compare GTBP & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTBP
  • ULY
  • Stock Information
  • Founded
  • GTBP 1965
  • ULY 2013
  • Country
  • GTBP United States
  • ULY United States
  • Employees
  • GTBP N/A
  • ULY N/A
  • Industry
  • GTBP Biotechnology: Pharmaceutical Preparations
  • ULY
  • Sector
  • GTBP Health Care
  • ULY
  • Exchange
  • GTBP Nasdaq
  • ULY Nasdaq
  • Market Cap
  • GTBP 5.5M
  • ULY 5.8M
  • IPO Year
  • GTBP N/A
  • ULY N/A
  • Fundamental
  • Price
  • GTBP $0.73
  • ULY $3.48
  • Analyst Decision
  • GTBP Strong Buy
  • ULY Strong Buy
  • Analyst Count
  • GTBP 1
  • ULY 2
  • Target Price
  • GTBP $11.00
  • ULY $11.50
  • AVG Volume (30 Days)
  • GTBP 641.6K
  • ULY 938.3K
  • Earning Date
  • GTBP 11-13-2025
  • ULY 11-11-2025
  • Dividend Yield
  • GTBP N/A
  • ULY N/A
  • EPS Growth
  • GTBP N/A
  • ULY N/A
  • EPS
  • GTBP N/A
  • ULY N/A
  • Revenue
  • GTBP N/A
  • ULY $131,235,000.00
  • Revenue This Year
  • GTBP N/A
  • ULY N/A
  • Revenue Next Year
  • GTBP N/A
  • ULY $20.23
  • P/E Ratio
  • GTBP N/A
  • ULY N/A
  • Revenue Growth
  • GTBP N/A
  • ULY N/A
  • 52 Week Low
  • GTBP $0.55
  • ULY $2.75
  • 52 Week High
  • GTBP $4.10
  • ULY $17.99
  • Technical
  • Relative Strength Index (RSI)
  • GTBP 35.99
  • ULY 44.98
  • Support Level
  • GTBP $0.62
  • ULY $2.75
  • Resistance Level
  • GTBP $0.68
  • ULY $3.62
  • Average True Range (ATR)
  • GTBP 0.08
  • ULY 0.45
  • MACD
  • GTBP 0.03
  • ULY 0.00
  • Stochastic Oscillator
  • GTBP 45.39
  • ULY 25.95

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: